てんかん薬市場、規模、シェア、動向、産業分析レポート：タイプ別、投与経路別、抗てんかん薬タイプ別、流通チャネル別、地域別、2025年～2034年の市場予測

Polaris Market Research社の最新調査によると、てんかん薬の世界市場規模は2034年までに194億5,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

てんかん薬市場は、脳の異常な活動を特徴とする神経疾患であるてんかんと診断された人の発作を管理・制御するために設計された医薬品で構成されています。抗てんかん薬（AED）としても知られるこれらの医薬品は、発作につながる過剰な電気的活動を防ぐため、脳内の神経信号を安定させることで機能します。市場には様々なタイプのAEDがあり、第一世代、第二世代、第三世代、また、対象とする発作のタイプによって異なるナロースペクトラム型とブロードスペクトラム型に分類されます。これらの薬剤は、経口剤、静脈内投与剤、筋肉内投与剤などさまざまな剤形があり、患者のニーズや病状に応じた柔軟な治療アプローチが可能です。

てんかん薬市場の需要は、てんかん有病率の上昇、薬剤製剤の進歩、神経疾患に対する意識の高まりなど、いくつかの要因によって牽引されています。同市場では、副作用が少なく、より安全で効果的な治療法を導入するため、継続的な研究開発が行われています。

さらに、高齢者人口の増加、ヘルスケア支出の増加、新興地域における医療へのアクセスの向上が市場拡大に拍車をかけています。規制当局の承認、新薬の上市、製薬企業と研究機関の提携は、競合情勢の形成に重要な役割を果たしています。治療戦略の進化に伴い、てんかん発作の制御を最適化し、患者の予後を改善することを目的とした革新的な薬剤開発や個別化医療アプローチによって、市場は恩恵を受けることが期待されます。

てんかん薬市場レポートハイライト

タイプ別では、第3世代の抗てんかん薬セグメントが、2024年のてんかん薬市場の売上高で最大のシェアを占めています。これは、旧世代と比較して安全性プロファイルが改善され、有効性が向上し、副作用が軽減されているためです。

投与経路別では、経口剤が最も一般的で利便性が高いことから、経口剤が圧倒的なシェアを占めています。錠剤や徐放性カプセルを含む幅広い経口剤形が利用可能なため、患者の治療レジメンへのアドヒアランスが向上し、市場シェアを牽引しています。

抗てんかん薬タイプ別では、広域スペクトル型AEDsの成長率が高くなっています。広域スペクトル型AEDsは複数の発作タイプに有効であり、狭域スペクトル型AEDsよりも汎用性が高いためです。特に薬剤耐性てんかんの場合、柔軟で包括的な治療オプションに対する需要が高まっていることが、このセグメントの急拡大に寄与している主な要因です。

地域別では、北米がてんかん薬市場で最大のシェアを占めているが、その主な理由は、先進的なヘルスケアインフラ、高い認知度、強固な研究開発イニシアティブにあります。

てんかん薬市場には、てんかん薬の開発・提供に積極的に取り組んでいる大手企業が複数存在します。主な企業は、UCB S.A.、サノフィ、ファイザー、エーザイ、アボット・ラボラトリーズ、ノバルティス、グラクソ・スミスクライン、サノビオン・ファーマシューティカルズ（住友製薬の子会社）、ジャズ・ファーマシューティカルズ、ニューロリス、武田薬品工業、Sun Pharmaceutical Industries Limitedなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のてんかん薬市場の洞察

• 市場スナップショット
• てんかん薬市場力学
  • 促進要因と機会
    • てんかんの有病率の増加
    • 抗てんかん薬開発の進歩
  • 抑制要因と課題
    • てんかん患者のかなりの割合に薬剤耐性がある
• PESTEL分析
• てんかん薬市場の応用動向
• バリューチェーン分析
• COVID-19の影響分析

第5章 世界のてんかん薬市場：タイプ別

• 主な調査結果
• イントロダクション
• 第一世代抗てんかん薬
• 第二世代抗てんかん薬
• 第三世代抗てんかん薬

第6章 世界のてんかん薬市場：投与経路別

• 主な調査結果
• イントロダクション
• 経口
• 静脈内
• 筋肉内

第7章 世界のてんかん薬市場：抗てんかん薬タイプ別

• 主な調査結果
• イントロダクション
• 狭域スペクトルAED
• 広域スペクトルAED

第8章 世界のてんかん薬市場：地域別

• 主な調査結果
• イントロダクション
  • てんかん薬市場分析：地域、2020年～2034年
• 北米
  • 北米：タイプ別、2020～2034年
  • 北米：投与経路別、2020～2034年
  • 北米：抗てんかん薬タイプ別、2020年～2034年
  • 米国
  • カナダ
• 欧州
  • 欧州：タイプ別、2020～2034年
  • 欧州：投与経路別、2020～2034年
  • 欧州：抗てんかん薬タイプ別、2020年～2034年
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • オランダ
  • ロシア
  • その他欧州
• アジア太平洋
  • アジア太平洋地域：タイプ別、2020～2034年
  • アジア太平洋地域：投与経路別、2020～2034年
  • アジア太平洋地域：抗てんかん薬タイプ別、2020年～2034年
  • 中国
  • インド
  • マレーシア
  • 日本
  • インドネシア
  • 韓国
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ
  • 中東・アフリカ：タイプ別、2020～2034年
  • 中東・アフリカ：投与経路別、2020～2034年
  • 中東・アフリカ：抗てんかん薬タイプ別、2020年～2034年
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他中東とアフリカ
• ラテンアメリカ
  • ラテンアメリカ：タイプ別、2020-2034年
  • ラテンアメリカ：投与経路別、2020～2034年
  • ラテンアメリカ：抗てんかん薬タイプ別、2020年～2034年
  • メキシコ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ

第9章 競合情勢

• 拡大と買収の分析
  • 拡大
  • 買収
• 提携/協業/合意/公開

第10章 企業プロファイル

• Abbott Laboratories
• Eisai Co., Ltd.
• GlaxoSmithKline plc
• Jazz Pharmaceuticals plc
• Neurelis Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Limited
• Sunovion Pharmaceuticals Inc.（a subsidiary of Sumitomo Pharma）
• Takeda Pharmaceutical Company
• UCB S.A.

List of Tables:

• Table 1 Global Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 2 Global Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 3 Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 4 North America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 5 North America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 6 North America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 7 U.S.: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 8 U.S.: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 9 U.S.: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 10 Canada: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 11 Canada: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 12 Canada: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 13 Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 14 Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 15 Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 16 UK: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 17 UK: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 18 UK: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 19 France: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 20 France: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 21 France: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 22 Germany: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 23 Germany: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 24 Germany: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 25 Italy: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 26 Italy: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 27 Italy: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 28 Spain: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 29 Spain: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 30 Spain: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 31 Netherlands: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 32 Netherlands: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 33 Netherlands: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 34 Russia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 35 Russia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 36 Russia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 37 Rest of Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 38 Rest of Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 39 Rest of Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 40 Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 41 Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 42 Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 43 China: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 44 China: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 45 China: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 46 India: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 47 India: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 48 India: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 49 Malaysia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 50 Malaysia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 51 Malaysia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 52 Japan: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 53 Japan: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 54 Japan: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 55 Indonesia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 56 Indonesia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 57 Indonesia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 58 South Korea: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 59 South Korea: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 60 South Korea: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 61 Australia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 62 Australia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 63 Australia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 64 Rest of Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 65 Rest of Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 66 Rest of Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 67 Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 68 Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 69 Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 70 Saudi Arabia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 71 Saudi Arabia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 72 Saudi Arabia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 73 UAE: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 74 UAE: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 75 UAE: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 76 Israel: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 77 Israel: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 78 Israel: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 79 South Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 80 South Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 81 South Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 82 Rest of Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 83 Rest of Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 84 Rest of Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 85 Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 86 Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 87 Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 88 Mexico: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 89 Mexico: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 90 Mexico: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 91 Brazil: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 92 Brazil: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 93 Brazil: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 94 Argentina: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 95 Argentina: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 96 Argentina: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• Table 97 Rest of Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• Table 98 Rest of Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• Table 99 Rest of Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)

List of Figures:

• Figure 1. Global Epilepsy Drugs Market, 2020-2034 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Price
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Type
• Figure 7. Global Epilepsy Drugs Market, by Type, 2024 & 2034 (USD Billion)
• Figure 8. Market by Route of Administration
• Figure 9. Global Epilepsy Drugs Market, by Route of Administration, 2024 & 2034 (USD Billion)
• Figure 10. Market by Antiepileptic Drugs Type
• Figure 11. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2024 & 2034 (USD Billion)

The global epilepsy drugs market size is expected to reach USD 19.45 billion by 2034, according to a new study by Polaris Market Research. The report "Epilepsy Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (First Generation Anti-epileptics, Second Generation Anti-epileptics, and Third Generation Anti-epileptics), Route of Administration, Antiepileptic Drugs Type, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The epilepsy drugs market comprises pharmaceutical products designed to manage and control seizures in individuals diagnosed with epilepsy, a neurological disorder characterized by abnormal brain activity. These drugs, also known as antiepileptic drugs (AEDs), function by stabilizing nerve signals in the brain to prevent excessive electrical activity that leads to seizures. The market includes various types of AEDs, categorized into first-generation, second-generation, and third-generation drugs, as well as narrow-spectrum and broad-spectrum AEDs, which differ based on their targeted seizure types. These medications are available in different formulations, including oral, intravenous, and intramuscular, allowing flexibility in treatment approaches based on patient needs and medical conditions.

The epilepsy drugs market demand is driven by several factors, including the rising prevalence of epilepsy, advancements in drug formulations, and increased awareness of neurological disorders. The market is witnessing continuous research and development efforts to introduce safer and more effective treatment options with minimal side effects.

Additionally, the growing elderly population, rising healthcare expenditures, and improved access to medical treatment in emerging regions are fueling market expansion. Regulatory approvals, new drug launches, and collaborations between pharmaceutical companies and research institutions play a crucial role in shaping the competitive landscape. As treatment strategies evolve, the market is expected to benefit from innovative drug development and personalized medicine approaches aimed at optimizing seizure control and improving patient outcomes.

Epilepsy Drugs Market Report Highlights

By type, The third generation anti-epileptics segment holds the largest share of the epilepsy drugs market revenue in 2024 due to their improved safety profiles, enhanced efficacy, and reduced side effects compared to earlier generations.

By route of administration, the oral segment dominates the epilepsy drugs market share as it is the most commonly used and convenient method for administering epilepsy drugs. The availability of a wide range of oral formulations, including tablets and extended-release capsules, enhances patient adherence to treatment regimens, driving its market share.

By antiepileptic drugs type, the broad-spectrum AEDs segment is experiencing a higher growth rate, as these drugs are effective in treating multiple types of seizures, making them more versatile than narrow-spectrum AEDs. The increasing demand for flexible and comprehensive treatment options, especially in cases of drug-resistant epilepsy, is a key factor contributing to this segment's rapid expansion.

By region, North America holds the largest share of the epilepsy drugs market, primarily due to its advanced healthcare infrastructure, high awareness levels, and robust research and development initiatives.

The epilepsy drugs market features several major companies actively involved in developing and providing treatments for epilepsy. A few key players include UCB S.A.; Sanofi; Pfizer Inc.; Eisai Co., Ltd.; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc; Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma); Jazz Pharmaceuticals plc; Neurelis Inc.; Takeda Pharmaceutical Company; and Sun Pharmaceutical Industries Limited.

Polaris Market Research has segmented the epilepsy drugs market report on the basis of type, route of administration, antiepileptic drugs type, distribution channel, and region:

By Type Outlook (Revenue-USD Billion, 2020-2034)

First Generation Anti-epileptics

Second Generation Anti-epileptics

Third Generation Anti-epileptics

By Route of Administration Outlook (Revenue-USD Billion, 2020-2034)

Oral

Intravenous

Intra-muscular

By Antiepileptic Drugs Type Outlook (Revenue-USD Billion, 2020-2034)

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

By Distribution Channel Outlook (Revenue-USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue-USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

Suth Korea

Indnesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

Suth Africa

Rest of Middle East & Africa

Latin America

Mexic

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Source
  • 3.2.1. Primary Source
  • 3.2.2. Secondary Source

4. Global Epilepsy Drugs Market Insights

• 4.1. Epilepsy Drugs Market - Market Snapshot
• 4.2. Epilepsy Drugs Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Prevalence of Epilepsy
    • 4.2.1.2. Advancements in Antiepileptic Drug Development
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Drug resistance in a significant percentage of epilepsy patients
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Epilepsy Drugs Market Application Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Epilepsy Drugs Market, by Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
• 5.3. First Generation Anti-epileptics
  • 5.3.1. Global Epilepsy Drugs Market, by First Generation Anti-epileptics, by Region, 2020-2034 (USD Billion)
• 5.4. Second Generation Anti-epileptics
  • 5.4.1. Global Epilepsy Drugs Market, by Second Generation Anti-epileptics, by Region, 2020-2034 (USD Billion)
• 5.5. Third Generation Anti-epileptics
  • 5.5.1. Global Epilepsy Drugs Market, by Third Generation Anti-epileptics, by Region, 2020-2034 (USD Billion)

6. Global Epilepsy Drugs Market, by Route of Administration

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
• 6.3. Oral
  • 6.3.1. Global Epilepsy Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
• 6.4. Intravenous
  • 6.4.1. Global Epilepsy Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)
• 6.5. Intra-muscular
  • 6.5.1. Global Epilepsy Drugs Market, by Intra-muscular, by Region, 2020-2034 (USD Billion)

7. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• 7.3. Narrow-Spectrum AEDs
  • 7.3.1. Global Epilepsy Drugs Market, by Narrow-Spectrum AEDs, by Region, 2020-2034 (USD Billion)
• 7.4. Broad-Spectrum AEDs
  • 7.4.1. Global Epilepsy Drugs Market, by Broad-Spectrum AEDs, by Region, 2020-2034 (USD Billion)

8. Global Epilepsy Drugs Market, by Geography

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Epilepsy Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
• 8.3. Epilepsy Drugs Market - North America
  • 8.3.1. North America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 8.3.2. North America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.3.3. North America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.3.4. Epilepsy Drugs Market - U.S.
    • 8.3.4.1. U.S.: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.3.4.2. U.S.: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.4.3. U.S.: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.3.5. Epilepsy Drugs Market - Canada
    • 8.3.5.1. Canada: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.3.5.2. Canada: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.5.3. Canada: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• 8.4. Epilepsy Drugs Market - Europe
  • 8.4.1. Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 8.4.2. Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.4.3. Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.4. Epilepsy Drugs Market - UK
    • 8.4.4.1. UK: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.4.2. UK: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.4.3. UK: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.5. Epilepsy Drugs Market - France
    • 8.4.5.1. France: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.5.2. France: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.5.3. France: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.6. Epilepsy Drugs Market - Germany
    • 8.4.6.1. Germany: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.6.2. Germany: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.6.3. Germany: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.7. Epilepsy Drugs Market - Italy
    • 8.4.7.1. Italy: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.7.2. Italy: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.7.3. Italy: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.8. Epilepsy Drugs Market - Spain
    • 8.4.8.1. Spain: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.8.2. Spain: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.8.3. Spain: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.9. Epilepsy Drugs Market - Netherlands
    • 8.4.9.1. Netherlands: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.9.2. Netherlands: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.9.3. Netherlands: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.10. Epilepsy Drugs Market - Russia
    • 8.4.10.1. Russia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.10.2. Russia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.10.3. Russia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.4.11. Epilepsy Drugs Market - Rest of Europe
    • 8.4.11.1. Rest of Europe: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.4.11.2. Rest of Europe: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.11.3. Rest of Europe: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• 8.5. Epilepsy Drugs Market - Asia Pacific
  • 8.5.1. Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 8.5.2. Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.5.3. Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.4. Epilepsy Drugs Market - China
    • 8.5.4.1. China: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.4.2. China: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.4.3. China: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.5. Epilepsy Drugs Market - India
    • 8.5.5.1. India: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.5.2. India: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.5.3. India: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.6. Epilepsy Drugs Market - Malaysia
    • 8.5.6.1. Malaysia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.6.2. Malaysia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.6.3. Malaysia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.7. Epilepsy Drugs Market - Japan
    • 8.5.7.1. Japan: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.7.2. Japan: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.7.3. Japan: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.8. Epilepsy Drugs Market - Indonesia
    • 8.5.8.1. Indonesia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.8.2. Indonesia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.8.3. Indonesia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.9. Epilepsy Drugs Market - South Korea
    • 8.5.9.1. South Korea: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.9.2. South Korea: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.9.3. South Korea: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.10. Epilepsy Drugs Market - Australia
    • 8.5.10.1. Australia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.10.2. Australia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.10.3. Australia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.5.11. Epilepsy Drugs Market - Rest of Asia Pacific
    • 8.5.11.1. Rest of Asia Pacific: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.5.11.2. Rest of Asia Pacific: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.11.3. Rest of Asia Pacific: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• 8.6. Epilepsy Drugs Market - Middle East & Africa
  • 8.6.1. Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 8.6.2. Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.6.3. Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.6.4. Epilepsy Drugs Market - Saudi Arabia
    • 8.6.4.1. Saudi Arabia: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.6.4.2. Saudi Arabia: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.4.3. Saudi Arabia: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.6.5. Epilepsy Drugs Market - UAE
    • 8.6.5.1. UAE: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.6.5.2. UAE: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.5.3. UAE: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.6.6. Epilepsy Drugs Market - Israel
    • 8.6.6.1. Israel: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.6.6.2. Israel: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.6.3. Israel: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.6.7. Epilepsy Drugs Market - South Africa
    • 8.6.7.1. South Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.6.7.2. South Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.7.3. South Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.6.8. Epilepsy Drugs Market - Rest of Middle East & Africa
    • 8.6.8.1. Rest of Middle East & Africa: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.6.8.2. Rest of Middle East & Africa: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.8.3. Rest of Middle East & Africa: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
• 8.7. Epilepsy Drugs Market - Latin America
  • 8.7.1. Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
  • 8.7.2. Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.7.3. Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.7.4. Epilepsy Drugs Market - Mexico
    • 8.7.4.1. Mexico: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.7.4.2. Mexico: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.4.3. Mexico: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.7.5. Epilepsy Drugs Market - Brazil
    • 8.7.5.1. Brazil: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.7.5.2. Brazil: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.5.3. Brazil: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.7.6. Epilepsy Drugs Market - Argentina
    • 8.7.6.1. Argentina: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.7.6.2. Argentina: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.6.3. Argentina: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)
  • 8.7.7. Epilepsy Drugs Market - Rest of Latin America
    • 8.7.7.1. Rest of Latin America: Epilepsy Drugs Market, by Type, 2020-2034 (USD Billion)
    • 8.7.7.2. Rest of Latin America: Epilepsy Drugs Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.7.3. Rest of Latin America: Epilepsy Drugs Market, by Antiepileptic Drugs Type, 2020-2034 (USD Billion)

9. Competitive Landscape

• 9.1. Expansion and Acquisition Analysis
  • 9.1.1. Expansion
  • 9.1.2. Acquisitions
• 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

• 10.1. Abbott Laboratories
  • 10.1.1. Company Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Benchmarking
  • 10.1.4. Recent Development
• 10.2. Eisai Co., Ltd.
  • 10.2.1. Company Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Benchmarking
  • 10.2.4. Recent Development
• 10.3. GlaxoSmithKline plc
  • 10.3.1. Company Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Benchmarking
  • 10.3.4. Recent Development
• 10.4. Jazz Pharmaceuticals plc
  • 10.4.1. Company Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Benchmarking
  • 10.4.4. Recent Development
• 10.5. Neurelis Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Benchmarking
  • 10.5.4. Recent Development
• 10.6. Novartis AG
  • 10.6.1. Company Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Benchmarking
  • 10.6.4. Recent Development
• 10.7. Pfizer Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Benchmarking
  • 10.7.4. Recent Development
• 10.8. Sanofi
  • 10.8.1. Company Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Benchmarking
  • 10.8.4. Recent Development
• 10.9. Sun Pharmaceutical Industries Limited
  • 10.9.1. Company Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Benchmarking
  • 10.9.4. Recent Development
• 10.10. Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Pharma)
  • 10.10.1. Company Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Benchmarking
  • 10.10.4. Recent Development
• 10.11. Takeda Pharmaceutical Company
  • 10.11.1. Company Overview
  • 10.11.2. Financial Performance
  • 10.11.3. Product Benchmarking
  • 10.11.4. Recent Development
• 10.12. UCB S.A.
  • 10.12.1. Company Overview
  • 10.12.2. Financial Performance
  • 10.12.3. Product Benchmarking
  • 10.12.4. Recent Development